Skip to main content
Premium Trial:

Request an Annual Quote

Movers & Shakers: Jan 15, 2010


Protagen this week announced the addition of two members to its executive board and one member to its supervisory board.

Joining the executive board are Peter Schulz-Knappe and Martin Blüggel. Schulz-Knappe will take on operational responsibility for the company's diagnostics business unit. He is the former chief scientific officer at Proteome Sciences.

Blüggel will manage the Business Unit Protein Services. He is a co-founder of Protagen and is the chief operating officer.

Thomas Schweins joined the supervisory board. He is a member of the executive committee at Qiagen, where he is also vice president of marketing and strategy.

SDI said this week that Klaus Lindpaintner is joining the firm as chief scientific officer, effective Feb. 1.

Lindpaintner had been with F. Hoffman-La Roche, most recently as director of the Roche Molecular Medicine Laboratories and as Roche's global head of Molecular Medicines Policy and External Affairs, where he coordinated biomarker research based on proteomics, genomics, genetics, and associated disciplines from early discovery to late-stage clinical trials.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.